Figure 6
Characterization of tumor progression and oncolysis on recombinant vaccinia virus (rVACV) and prodrug treatment. Groups of 12 GI-101A tumor-bearing mice (two tumors on each) were injected intravenously with phosphate-buffered saline (PBS), or 5 × 106 PFUs of GLV-1h43 and GLV-1h68. Although one subgroup of six mice received prodrug treatment, the other subgroup received injections of 50% dimethyl sulfoxide/50% PBS only. Tumor size was measured weekly until 70 dpi for rVACV-infected mice or until the mice had to be killed because of tumor burden in PBS-injected control groups. Injection of prodrug led to reduced tumor size in all subgroups compared with untreated mice, but reached no statistical significance except in the GLV-1h68-treated group on day 70 after rVACV injection. Depicted are average values plus standard deviation. Asterisk indicates statistical significance (P<0.05) between prodrug-treated and untreated subgroups.
